Study identifier:D5980R00145
ClinicalTrials.gov identifier:NCT07933510
EudraCT identifier:N/A
CTIS identifier:N/A
BENTEN study: Changes in symptom and quality of life in patients with uncontrolled asthma treated with Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler (BGF MDI): a prospective, multi-centers, observational study
asthma
-
no
Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler
All
200
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|---|
| Patients with asthma newly initiated on BGF MDI The study population will include approximately 200 adult patients with asthma in Japan who are newly initiated BGF MDI treatment, have an ACQ-5 score ≥1.5 at enrollment. | Drug: Budesonide/Glycopyrronium/Formoterol fumarate metered dose inhaler Initiation of BGF MDI treatment in routine clinical practice. Other Name: BGF MDI |